Literature DB >> 1906375

Concentrations of pravastatin and lovastatin in cerebrospinal fluid in healthy subjects.

R E Botti1, J Triscari, H Y Pan, J Zayat.   

Abstract

The capability of pravastatin and lovastatin, HMG-CoA reductase inhibitors likely to be taken chronically for hypercholesterolemia, to cross the blood-brain barrier was investigated in normal male volunteers. Lovastatin, which is lipophilic, was detected in cerebrospinal fluid (CSF) at concentrations that may have a pharmacologic effect. Pravastatin, which is hydrophilic, was not detected in CSF. It is concluded that pravastatin may have less potential for causing CNS-related side effects than lovastatin.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1906375     DOI: 10.1097/00002826-199106000-00010

Source DB:  PubMed          Journal:  Clin Neuropharmacol        ISSN: 0362-5664            Impact factor:   1.592


  34 in total

1.  Long-term atorvastatin treatment leads to alterations in behavior, cognition, and hippocampal biochemistry.

Authors:  Jan M Schilling; Weihua Cui; Joseph C Godoy; Victoria B Risbrough; Ingrid R Niesman; David M Roth; Piyush M Patel; John C Drummond; Hemal H Patel; Alice E Zemljic-Harpf; Brian P Head
Journal:  Behav Brain Res       Date:  2014-03-19       Impact factor: 3.332

2.  High doses of simvastatin upregulate dopamine D1 and D2 receptor expression in the rat prefrontal cortex: possible involvement of endothelial nitric oxide synthase.

Authors:  Qing Wang; Wee Lee Ting; Hongyuan Yang; Peter T-H Wong
Journal:  Br J Pharmacol       Date:  2005-04       Impact factor: 8.739

Review 3.  Clinical pharmacokinetics of 3-hydroxy-3-methylglutaryl-coenzyme A reductase inhibitors.

Authors:  J P Desager; Y Horsmans
Journal:  Clin Pharmacokinet       Date:  1996-11       Impact factor: 6.447

4.  Evaluation of HMG-CoA reductase inhibitors for multiple sclerosis: opportunities and obstacles.

Authors:  Oliver Neuhaus; Olaf Stüve; Scott S Zamvil; Hans-Peter Hartung
Journal:  CNS Drugs       Date:  2005       Impact factor: 5.749

Review 5.  Alzheimer's disease and cholesterol: the fat connection.

Authors:  Laura Canevari; John B Clark
Journal:  Neurochem Res       Date:  2006-12-27       Impact factor: 3.996

Review 6.  Pediatric Statin Administration: Navigating a Frontier with Limited Data.

Authors:  Jonathan Wagner; Susan M Abdel-Rahman
Journal:  J Pediatr Pharmacol Ther       Date:  2016 Sep-Oct

7.  Effects of treatment with simvastatin and pravastatin on cognitive function in patients with hypercholesterolaemia.

Authors:  N Cutler; J Sramek; A Veroff; G Block; L Stauffer; C Lines
Journal:  Br J Clin Pharmacol       Date:  1995-03       Impact factor: 4.335

8.  Lovastatin-induced apoptosis of human medulloblastoma cell lines in vitro.

Authors:  R J Macaulay; W Wang; J Dimitroulakos; L E Becker; H Yeger
Journal:  J Neurooncol       Date:  1999-03       Impact factor: 4.130

Review 9.  Pravastatin: a review of its use in elderly patients.

Authors:  Lynne M Bang; Karen L Goa
Journal:  Drugs Aging       Date:  2003       Impact factor: 3.923

Review 10.  Brain cholesterol metabolism, oxysterols, and dementia.

Authors:  Timothy M Hughes; Caterina Rosano; Rhobert W Evans; Lewis H Kuller
Journal:  J Alzheimers Dis       Date:  2013       Impact factor: 4.472

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.